PIP caused a doubling down ripple effect across approvals IMHO, particularly in Europe. However, as TIS have stated that "Target for start of sales in the USA with reimbursement, 26 months from start of pivotal trial" and as many other Juristrictions accept CE as FDA there now looks to be little difference between paths.
The way I see it., page-27
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
